SLSteffen Lemke

Steffen Lemke

*This is an algorithmically generated author record based on publicly available information.

Steffen Lemke has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • Juliane Stickel Walz

    Cluster of Excellence iFIT (EXC2180) ‘Image-Guided and Functionally Instructed Tumor Therapies’, University of Tübingen, Tübingen, Germany

    4 shared publications
  • Anna Dengler

    Department of Peptide-based Immunotherapy, Institute of Immunology, University and University Hospital Tübingen, Tübingen, BW, Germany

    3 shared publications
  • Annika Nelde

    Cluster of Excellence iFIT (EXC2180) ‘Image-Guided and Functionally Instructed Tumor Therapies’, University of Tübingen, Tübingen, Germany

    3 shared publications
  • Hans-Georg Rammensee

    Institute of Immunology, University of Tübingen, Tübingen, Germany

    3 shared publications
  • Jens Bauer

    Department of Peptide-based Immunotherapy, Institute of Immunology, University and University Hospital Tübingen, Tübingen, Germany 2. Cluster of Excellence iFIT (EXC2180) “Image-Guided and Functionally Instructed Tumor Therapies”, University of Tübingen, Tübingen, Germany

    3 shared publications
  • Jonas Scheid

    Department of Peptide-based Immunotherapy, Institute of Immunology, University and University Hospital Tübingen, Tübingen, Germany

    3 shared publications

Latest Publications

  • Open Access

    Deep learning enables direct HLA typing from immunopeptidomics data

    by Matteo Pilz, Jonas Scheid, Alina Bauer, Steffen Lemke, Timo Sachsenberg, Jens Bauer, Annika Nelde, Josua Stadelmaier, Axel Walter, Hans-Georg Rammensee, et al.

    The immune system eliminates malignant and infected cells through T-cell-mediated recognition of peptides presented by human leukocyte antigen molecules. Mass spectrometry-based immunopeptidomics enables unbiased identification of naturally presented HLA-restricted peptides and has become central to the development of T-cell-based immunotherapies. However, immunopeptidomics data reflects the combined peptide presentation of multiple HLA alleles, and determining which allotypes are represented in this multi-allelic complexity remains an unmet computational challenge. Here, we introduce immunotype, a deep learning-based ensemble predictor for HLA class I allotyping directly from immunopeptidomics data. Immunotype integrates peptide and HLA sequence information through transformer encoders and a graph neural network, complemented by a curated mono-allelic reference of known peptide-HLA binding preferences. Immunotype achieves an overall accuracy of 87.2% at protein-level resolution across diverse tissues and thereby enables rapid, cost-effective HLA typing of large-scale immunopeptidomics datasets.

  • Open Access

    PCI-DB: a novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development

    by Steffen Lemke, Marissa L Dubbelaar, Patrick Zimmermann, Jens Bauer, Annika Nelde, Naomi Hoenisch Gravel, Jonas Scheid, Marcel Wacker, Susanne Jung, Anna Dengler, et al.

    Background Various cancer immunotherapies rely on the T cell-mediated recognition of peptide antigens presented on human leukocyte antigens (HLA). However, the identification and selection of naturally presented peptide targets for the development of personalized as well as off-the-shelf immunotherapy approaches remain challenging. Methods Over 10,000 raw mass spectrometry (MS) files from over 3,000 tissue samples were analyzed, summing to approximately seven terabytes of data. The raw MS data were processed using the standardized and open-source nf-core pipelines MHCquant2 and epitopeprediction, providing a uniform procedure for data handling. A global false discovery rate was applied to minimize false-positive identifications. Results Here, we introduce the open-access Peptides for Cancer Immunotherapy Database (PCI-DB, https://pci-db.org/), a comprehensive resource of immunopeptidome data originating from various malignant and benign primary tissues that provides the research community with a convenient tool to facilitate the identification of peptide targets for immunotherapy development. The PCI-DB includes >6.6 million HLA class I and >3.4 million HLA class II peptides from over 40 tissue types and cancer entities. First application of the database provided insights into the representation of cancer-testis antigens across malignant and benign tissues, enabling the identification and characterization of cross-tumor entity and entity-specific tumor-associated antigens (TAAs) as well as naturally presented neoepitopes from frequent cancer mutations. Further, we used the PCI-DB to design personalized peptide vaccines for two patients suffering from metastatic cancer. In a retrospective analysis, PCI-DB enabled the composition of both a multi-peptide vaccine comprising non-mutated, highly frequent TAAs matching the immunopeptidome of the individual patient’s tumor and a neoepitope-based vaccine matching the mutational profile of a patient with cancer. Both vaccine approaches induced potent and long-lasting T-cell responses, accompanied by long-term survival of these patients with advanced cancer. Conclusion The PCI-DB provides a highly versatile tool to broaden the understanding of cancer-related antigen presentation and, ultimately, supports the development of novel immunotherapies.


  • Open Access

    PCI-DB: A novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy development

    by Steffen Lemke, Marissa L. Dubbelaar, Patrick Zimmermann, Jens Bauer, Annika Nelde, Naomi Hoenisch Gravel, Jonas Scheid, Marcel Wacker, Susanne Jung, Anna Dengler, et al.

    Various cancer immunotherapies rely on the T cell-mediated recognition of peptide antigens presented on human leukocyte antigens (HLA). However, the identification and selection of naturally presented peptide targets for the development of personalized as well as off-the-shelf immunotherapy approaches remains challenging. Here, we introduce the open-access Peptides for Cancer Immunotherapy Database (PCI-DB, https://pci-db.org/), a comprehensive resource of immunopeptidome data originating from various malignant and benign primary tissues that provides the research community with a convenient tool to facilitate the identification of peptide targets for immunotherapy development. The PCI-DB includes > 6.6 million HLA class I and > 3.4 million HLA class II peptides from over 40 tissue types and cancer entities analyzed uniformly using high-sensitive nf-core bioinformatics pipelines and applying a global peptide false discovery rate. First application of the database provided insights into the representation of cancer-testis antigens across malignant and benign tissues, enabling the identification and characterization of cross-tumor entity and entity-specific tumor-associated antigens as well as naturally presented neoepitopes from frequent cancer mutations. Further, we used the PCI-DB to design personalized peptide vaccines for two patients suffering from metastatic cancer. In a retrospective analysis, PCI-DB enabled the composition of both a multi-peptide vaccine comprising non-mutated, highly frequent tumor-associated antigens matching the immunopeptidome of the individual patient´s tumor and a neoepitope-based vaccine matching the mutational profile of a cancer patient. Both vaccine approaches induced potent and long-lasting T-cell responses, accompanied by long-term survival of these advanced cancer patients. In conclusion, the PCI-DB provides a highly versatile tool to broaden the understanding of cancer-related antigen presentation and, ultimately, supports the development of novel immunotherapies.


  • Open Access

    MHCquant2 refines immunopeptidomics tumor antigen discovery

    by Jonas Scheid, Steffen Lemke, Naomi Hoenisch-Gravel, Anna Dengler, Timo Sachsenberg, Arthur Declerq, Ralf Gabriels, Jens Bauer, Marcel Wacker, Leon Bichmann, et al.

    The identification of human leukocyte antigen (HLA)-presented peptides as targets of anti-cancer T cell response is pivotal for the development of novel immunotherapies. Mass spectrometry (MS)-based immunopeptidomics enables the detection of these peptides, yet confident identifications and thus implementation in immunotherapy design are hampered by the high diversity and low abundance of naturally presented HLA peptides. Here, we introduce MHCquant2, a Nextflow-based open-source pipeline that leverages OpenMS tools and peptide property predictors (DeepLC, MS2PIP) for highly sensitive and scalable HLA peptide identification and quantification across various MS platforms. MHCquant2 increased peptide identifications up to 27% with a significant expansion of low-abundant peptides, outperforming state-of-the-art pipelines. Using MHCquant2 we build a comprehensive benign tissue repository comprising re-analyzed data from available benign immunopeptidomes and a novel benignMHCquant2 dataset, adding more than 160,000 novel naturally presented HLA peptides. First applications of this benign repository and the MHCquant2 pipeline enabled (i) the refinement of tumor-associated antigens, (ii) the detection of novel, high-frequent tumor-exclusive peptide antigens for multiple tumor entities, and (iii) the identification and quantification of mutation-derived low-abundant neoepitopes. MHCquant2 refines tumor antigen discovery in immunopeptidomics, paving the way for the implementation of off-the-shelf and personalized immunotherapy design.


  • Open Access

    Chromosome 8p engineering reveals increased metastatic potential targetable by patient-specific synthetic lethality in liver cancer

    by Thorben Huth, Emely C. Dreher, Steffen Lemke, Sarah Fritzsche, Raisatun N. Sugiyanto, Darko Castven, David Ibberson, Carsten Sticht, Eva Eiteneuer, Anna Jauch, et al.

    Large-scale chromosomal aberrations are prevalent in human cancer, but their function remains poorly understood. We established chromosome-engineered hepatocellular carcinoma cell lines using CRISPR-Cas9 genome editing. A 33–mega–base pair region on chromosome 8p (chr8p) was heterozygously deleted, mimicking a frequently observed chromosomal deletion. Using this isogenic model system, we delineated the functional consequences of chr8p loss and its impact on metastatic behavior and patient survival. We found that metastasis-associated genes on chr8p act in concert to induce an aggressive and invasive phenotype characteristic for chr8p-deleted tumors. Genome-wide CRISPR-Cas9 viability screening in isogenic chr8p-deleted cells served as a powerful tool to find previously unidentified synthetic lethal targets and vulnerabilities accompanying patient-specific chromosomal alterations. Using this target identification strategy, we showed that chr8p deletion sensitizes tumor cells to targeting of the reactive oxygen sanitizing enzyme Nudix hydrolase 17. Thus, chromosomal engineering allowed for the identification of novel synthetic lethalities specific to chr8p loss of heterozygosity.